Izopet 2000.

Methods	N=38 Non randomised, Fup=6 months, w/o: reported
Participants	Eligibility:‐ HIV RNA >5000 copies/ml, Age: 41 years, Sex: 82% males ART : ART for >6months, NRTI + PI used, Baseline CD4 median 188(6‐732) Baseline VL 4.6(3.7‐6.2);
Interventions	3 month TI
Outcomes	CD4 decline: 43 cells/mm3 VL rebound: 0.4 log copies/ml Viral reversion:61% participants
Notes	Clinical stage predicts viral reversion
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	D ‐ Not used